CN109476677A - 抗hcmv病毒化合物 - Google Patents

抗hcmv病毒化合物 Download PDF

Info

Publication number
CN109476677A
CN109476677A CN201780045987.0A CN201780045987A CN109476677A CN 109476677 A CN109476677 A CN 109476677A CN 201780045987 A CN201780045987 A CN 201780045987A CN 109476677 A CN109476677 A CN 109476677A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
acceptable salt
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780045987.0A
Other languages
English (en)
Other versions
CN109476677B (zh
Inventor
熊剑
王晶晶
伍文韬
谭海忠
彭宣嘉
张杨
陈新海
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huinuo Biomedical Technology Hangzhou Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN109476677A publication Critical patent/CN109476677A/zh
Application granted granted Critical
Publication of CN109476677B publication Critical patent/CN109476677B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

一类抗HCMV病毒的并环类化合物，及其在制备治疗与HCMV病毒相关疾病的药物中的应用。具体为式(Ⅱ)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (44)

  1. PCT国内申请，权利要求书已公开。
CN201780045987.0A 2016-08-08 2017-08-08 抗hcmv病毒化合物 Active CN109476677B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610644091 2016-08-08
CN2016106440911 2016-08-08
PCT/CN2017/096366 WO2018028556A1 (zh) 2016-08-08 2017-08-08 抗hcmv病毒化合物

Publications (2)

Publication Number Publication Date
CN109476677A true CN109476677A (zh) 2019-03-15
CN109476677B CN109476677B (zh) 2024-06-07

Family

ID=

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917527A (zh) * 2011-09-16 2014-07-09 拜耳知识产权有限责任公司 取代的5-氟-嘧啶
WO2015043364A1 (zh) * 2013-09-29 2015-04-02 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
CN104860935A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途
US20160016975A1 (en) * 2013-03-15 2016-01-21 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
CN105793265A (zh) * 2013-12-10 2016-07-20 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917527A (zh) * 2011-09-16 2014-07-09 拜耳知识产权有限责任公司 取代的5-氟-嘧啶
US20160016975A1 (en) * 2013-03-15 2016-01-21 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as bace inhibitors, compositions, and their use
WO2015043364A1 (zh) * 2013-09-29 2015-04-02 华北制药集团新药研究开发有限责任公司 作为凝血因子Xa抑制剂的苯并恶唑并恶嗪酮类化合物
CN104693211A (zh) * 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
CN105793265A (zh) * 2013-12-10 2016-07-20 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
CN104860935A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途

Also Published As

Publication number Publication date
WO2018028556A1 (zh) 2018-02-15
EP3498715A1 (en) 2019-06-19
ES2882531T3 (es) 2021-12-02
JP2019524810A (ja) 2019-09-05
US10851112B2 (en) 2020-12-01
JP6951418B2 (ja) 2021-10-20
US20190202838A1 (en) 2019-07-04
EP3498715A4 (en) 2019-06-26
EP3498715B1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
JP7264642B2 (ja) エフェクターｔ細胞機能を増進するための、セレブロンを標的とする小分子
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
CN109790159A (zh) 抗流感病毒嘧啶衍生物
CN109071564A (zh) 乙型肝炎病毒表面抗原抑制剂
CN101087766B (zh) 哒嗪化合物、组合物和方法
CN104379583B (zh) 作为wnt信号传导抑制剂的化合物、组合物及其应用
CN107531711A (zh) Janus激酶抑制剂
CN106470992B (zh) 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
MXPA06011829A (es) Derivados de 1-amino-ftalazina, su preparacion, y su aplicacion terapeutica.
CN110446712A (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
CN109790155A (zh) 噻吩化合物及其合成方法和其在医药上的应用
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
CN101223147A (zh) 作为激肽原2受体拮抗剂的嘧啶酮衍生物
CN111542520B (zh) 作为a2a受体抑制剂的并环类衍生物
BR112018075736B1 (pt) Composto de amida alfa e beta insaturado derivado de benzotriazol usado como inibidor de tgf-betar1
US10604513B2 (en) Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN108602757B (zh) 地佐辛类似物
CN109311881A (zh) 新型β-内酰胺酶抑制剂
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
CN110382463A (zh) Hdac6选择性抑制剂及其制备方法和应用
WO1998009960A1 (fr) Derives de pyrimidine 2,4-bisubstitues, procede pour leur production et compositions medicales les contenant
CN110418790A (zh) 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物
CN105873439A (zh) RORγt的烷基连接的喹啉基调节剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 210032 room 218, business office, building 9, Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant after: Nanjing Mingde New Drug Development Co.,Ltd.

Address before: Room 218, No. 9 Commercial Office Building, Gaoxin Road, Nanjing High-tech Development Zone, Jiangsu Province

Applicant before: MEDSHINE DISCOVERY Inc.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20211221

Address after: 310018 room 1-404, Heda Medicine Valley Center, 291 Fucheng Road, Xiasha street, Hangzhou Economic and Technological Development Zone, Zhejiang Province

Applicant after: Huinuo biomedical technology (Hangzhou) Co.,Ltd.

Address before: 210032 room 218, business office, building 9, Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant